City

Boston (1)

Houston (1)

Los Angeles (1)

Milan (1)

Turku (1)

Condition

CNS Disease (5)

Breast Cancer (2)

Brain Diseases (1)

Brain Metastases (1)

CNS Infection (1)

COVID-19 Testing (1)

Glioblastoma (1)

HER2-positive Breast Cancer (1)

Overall Status

Terminated (2)

Completed (1)

Recruiting (1)

Withdrawn (1)

Phase

phase 1 (2)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

IRCCS San Raffaele (1)

M.D. Anderson Cancer Center (1)

Nancy Lin, MD (1)

Orion Corporation, Orion Pharma (1)

Reva Basho (1)

Collaborator

Bayer (1)

Breast Cancer Research Foundation (1)

Brigham and Women's Hospital (1)

Bristol-Myers Squibb (1)

Merck Sharp & Dohme LLC (1)

Seagen Inc. (1)

Study Documents

Intervention Type

drug (4)

diagnostic test (1)

radiation (1)

Funder Type

Other (4)

Industry (1)

Study Type

Interventional (4)

Observational (1)

cns disease

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Los Angeles (Tucatinib, Pembrolizumab, Trastuzumab)

Withdrawn

Breast Cancer
+3 more

Tucatinib
+2 more

Los Angeles, California

Cedars-Sinai Medical Center

Jun 28, 2022

CNS Disease Trial in Turku (ODM-104, Paracetamol)

Completed

CNS Disease

Turku, Finland

CRST Turku

Apr 12, 2021

Virus in Central Nervous System

Recruiting

COVID-19 Testing
+2 more

Determination of SARS-CoV2 presence in CNS

Milan, Italy

IRCCS San Raffaele Scientific Institute

Feb 27, 2021

Glioblastoma, CNS Disease, Brain Diseases Trial in Houston (Dasatinib, RT (Radiotherapy), TMZ (Temozolomide))

Terminated

Glioblastoma
+2 more

Dasatinib
+2 more

Houston, Texas

UT MD Anderson Cancer Center

Nov 7, 2018

Breast Cancer, CNS Disease Trial in Boston (ZK219477)

Terminated

Has Results

Breast Cancer
CNS Disease

ZK219477

Boston, Massachusetts

Dana-Farber Cancer Institute

Mar 12, 2013